Not Available

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$150,000.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
N43CO201000125
Agency Tracking Number:
N43CO201000125
Solicitation Year:
2010
Solicitation Topic Code:
NCI
Solicitation Number:
PHS2010-1
Small Business Information
OCEAN NANOTECH, LLC
2143 Worth Lane, SPRINGDALE, AR, 72764-
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
Y
Duns:
155516987
Principal Investigator:
Y. Andrew Wang
(479) 236-7147
AWANG@OCEANNANOTECH.COM
Business Contact:
(479) 236-7147
AWANG@OCEANNANOTECH.COM
Research Institution:
n/a
Abstract
Quantum dots (ODs) with unique optical properties such as size-tunable emission , simultaneous excitation, high brightness, and very slow photobleaching ¿can be used as powerful cancer diagnostic tools providing the -"'¿cile-cular¿ profiles of cancer cases based on common clinical biopsies and allowing the tumor cell detection ¿and-analysis in highly heterogenous samples and rare cell populations. However, researchers have found that the¿ fluorescence intensity of QDs changes under light irradiation and the QD-antibody conjugates detaches from tissues easily during the staining process, making it very difficult to quantify expression level of biomarkers. To develop QD based multiplexing and quantitative kits for clinical applications, this team proposes to increase the QD stability through the multi-shell coating strategy in Aim 1 and to develop the high-bioaffinity QD-Antibody (Ab) through the adaptor protein strategy in Aim 2. As the first application, the improved QO-Ab technology will be used to develop a multi-biomarker imaging kit for prediction of human papilomavirus (HPV)- associated cancer. HPV is one of the risk factors in cancer development. Accurate evaluation of the impact of HPV on cancer development requires incorporation of our knowledge of the pathways by which HPV causes cancer. This team would like to use three QD-conjugated antibodies which specifically bind to HPV-related proteins as a predictor for cancer assessment. As a preparation for the phase II development of this technology, Aim 3 and 4 will validate Ihe HPV specific QD-Abs and oplimize Ihe condition for multiple QD-staining and quantification, respectively, by using human cancer cell lines and tissues.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government